Technological advancements and the rise in minimally invasive surgery cases will spur the spine biologics market growth.
Here are five key points:
1. An increasing geriatric population and government funding will also boost the market.
2. The Americas is experiencing the highest demand for spine biologics and captures the largest market share.
3. Between 2016 and 2026, North America will see growth in the spine biologics segment due to an increasing population, growing awareness of new technologies and rising per capita income of hospitals and the population.
4. The procedures' costliness and availability of substitute products will hinder market growth.
5. Alphatech Spine, Medtronic, Zimmer Biomet, Globus Medical, Exactech, RTI Biologics, Small Bone Innovations, Stryker, Amedica, K2M, NuVasive, Precision Spine and TranS1 dominate the market.